A shocking move by the Trump administration has sparked debate over its decision to repurpose an old generic drug—leucovorin—as a potential treatment for autism. This bold step caught many experts off guard, including the doctor who first proposed the idea to top health officials. Dr. Richard Frye, a child neurologist based in Arizona, shared that he had been discussing this with federal regulators for years, hoping to develop a customized version for autistic children. But he was stunned when the administration approved the drug without waiting for further research.
This isn’t just one of many examples of the chaotic rollout of the Trump administration’s autism policies. Critics argue that the decision elevates an unproven treatment to a credible option for a complex neurological condition. While the administration hasn’t responded to requests for comment, leading autism organizations have distanced themselves from the move, calling the supporting studies 'very weak' and 'too small.' David Mandell, a psychiatrist at the University of Pennsylvania, emphasized that there’s no moderate evidence linking leucovorin to autism relief.
Yet, a growing number of doctors are prescribing the drug, often using versions originally designed for chemotherapy or ordering custom formulations from compounding pharmacies. Researchers agree that more study is needed, especially for patients with folate deficiencies, but stress that it should only be used in controlled trials. 'Our job is to stay between the yellow lines,' said Dr. Lawrence Gray, a pediatric specialist. 'When people bypass guidelines, they risk unknown consequences.'
The science behind leucovorin is mixed. While it converts into folate—a nutrient critical for prenatal development—it’s unclear how it affects brain function after birth. Frye and others revived the theory decades ago, suggesting that autism might be linked to folate absorption issues. However, later research showed that siblings of autistic individuals can also have low folate levels without symptoms, casting doubt on the connection. A 2018 study of 48 children found that those taking leucovorin performed better on language tests, but other small studies from China and Iran produced conflicting results due to varying dosages and methods.
Frye struggled to secure funding within traditional academic systems, leading him to launch the Autism Discovery Coalition to pitch his work to Trump’s health officials. After meeting with Health Secretary Robert F. Kennedy Jr., discussions shifted toward testing a purified version of the drug. This could generate significant profits, as the drug’s current generic form is cheap. But the FDA’s recent announcement may have derailed these plans. Instead of approving a new version, the agency updated the label to mention its potential use in boosting folate levels, aiming to encourage wider prescription and insurance coverage.
Experts warn that promising treatments often fail when tested on larger populations. 'Small studies often find motivated groups,' said Gray. 'But when therapies are scaled up, the initial gains often vanish.' One major hurdle is the lack of consensus on how many autistic patients have the folate-blocking antibodies the drug targets. Frye uses a specialized test developed at a New York lab, though it hasn’t been reviewed by the FDA. Gray noted that the only way to definitively test for these antibodies would be through spinal taps, which limits large-scale studies.
Meanwhile, online platforms are driving interest among parents. Brian Noonan, a parent of a 4-year-old with autism, discovered leucovorin after asking ChatGPT for treatment options. After a blood test confirmed his son’s eligibility, he started the drug through a compounding pharmacy. Within days, he reported improvements in eye contact and speech. 'It’s not a cure, but these are meaningful steps,' he said.
As the debate continues, one question lingers: Should unproven treatments be fast-tracked for autism, even without solid evidence? What do you think about this approach? Share your views in the comments.
